Head to Head Review: Molecular Templates (MTEM) & Affimed (NASDAQ:AFMD)

Affimed (NASDAQ: AFMD) and Molecular Templates (NASDAQ:MTEM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Valuation & Earnings

This table compares Affimed and Molecular Templates’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Affimed $2.27 million 57.72 -$34.16 million ($0.78) -2.69
Molecular Templates $3.39 million 69.37 -$23.14 million ($2.11) -4.12

Molecular Templates has higher revenue and earnings than Affimed. Molecular Templates is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Affimed and Molecular Templates’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Affimed -1,493.69% -80.04% -61.56%
Molecular Templates N/A -54.49% -45.65%

Analyst Recommendations

This is a summary of current ratings for Affimed and Molecular Templates, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Affimed 0 2 1 0 2.33
Molecular Templates 0 1 1 0 2.50

Affimed presently has a consensus target price of $6.50, suggesting a potential upside of 209.52%. Molecular Templates has a consensus target price of $5.20, suggesting a potential downside of 40.16%. Given Affimed’s higher possible upside, equities analysts plainly believe Affimed is more favorable than Molecular Templates.

Insider & Institutional Ownership

27.9% of Affimed shares are owned by institutional investors. Comparatively, 16.2% of Molecular Templates shares are owned by institutional investors. 13.0% of Molecular Templates shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Affimed has a beta of 2.3, meaning that its share price is 130% more volatile than the S&P 500. Comparatively, Molecular Templates has a beta of 3.16, meaning that its share price is 216% more volatile than the S&P 500.

Summary

Molecular Templates beats Affimed on 9 of the 13 factors compared between the two stocks.

Affimed Company Profile

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

Molecular Templates Company Profile

Molecular Templates, Inc., formerly Threshold Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs). The Company is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. The Company’s lead drug candidate MT-3724 is an is an immunotoxin that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias.

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.